Value proposition

Cardiawave is developing an innovative and non-invasive ultrasound treatment of aortic stenosis.

Innovation prize winner of many contests, Cardiawave is a clinical-stage company which develops an innovative non-invasive image-guided medical device (MD) to treat aortic valve stenosis with ultrasound technology. Aortic stenosis is a life-threatening disease which is a major public health concern in Western countries (10 million people affected). The MD uses focused ultrasound therapy to soften aortic valve leaflets and improve valve opening. The company was created at the end of 2014 as a result of a long-term partnership between the Langevin Institute / Physics for Medicine Paris, a world leader in ultrasound imaging and therapy, and the Georges Pompidou European Hospital (HEGP), a leader in the field of valve disease and cardiac ultrasound imaging.